MNOV Similar Chart Price Prediction
The price of MNOV is predicted to go up 4.93%, based on the high correlation periods with MHLD. The similarity of these two price pattern on the periods is 97.25%.
MNOV
MHLD
Up: 4.93%Similarity: 97.25%
MNOV Revenue Forecast
MNOV EPS Forecast
MNOV Analyst's Forecast
Jason Kolbert
D. Boral Capital
Strong Buy
Price Target
$9
Upside
+278.15%
D. Boral Capital initiated coverage of MediciNova with a Buy rating and $9 price target. The company is retasking an old drug, Ibudilast - originally used in Japan for asthma, to treat amyotrophic lateral sclerosis, the analyst tells investors in a research note. The firm says the data in ALS shows a significant efficacy signal while the drug is known to be very safe. This combination suggests it may find broad use in ALS and, ultimately, some of the other target indications, such as multiple sclerosis, contends D. Boral.